Pre-Market Activity Shows Heavy Volume And Movement For Insys Therapeutics (INSY)

Trade-Ideas LLC identified Insys Therapeutics (INSY) as a pre-market mover with heavy volume candidate
By TheStreet Wire ,

Trade-Ideas LLC identified

Insys Therapeutics

(

INSY

) as a pre-market mover with heavy volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Insys Therapeutics as such a stock due to the following factors:

  • INSY has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $9.1 million.
  • INSY traded 77,691 shares today in the pre-market hours as of 8:06 AM, representing 12.8% of its average daily volume.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in INSY with the Ticky from Trade-Ideas. See the FREE profile for INSY NOW at Trade-Ideas

More details on INSY:

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. INSY has a PE ratio of 17. Currently there are 3 analysts that rate Insys Therapeutics a buy, no analysts rate it a sell, and 1 rates it a hold.

The average volume for Insys Therapeutics has been 661,400 shares per day over the past 30 days. Insys has a market cap of $895.8 million and is part of the health care sector and drugs industry. The stock has a beta of 0.74 and a short float of 157.4% with 29.52 days to cover. Shares are down 54.8% year-to-date as of the close of trading on Thursday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Insys Therapeutics as a

hold

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and a generally disappointing performance in the stock itself.

Highlights from the ratings report include:

  • INSY has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 2.73, which clearly demonstrates the ability to cover short-term cash needs.
  • The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Biotechnology industry and the overall market on the basis of return on equity, INSYS THERAPEUTICS INC has underperformed in comparison with the industry average, but has exceeded that of the S&P 500.
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 69.7% when compared to the same quarter one year ago, falling from $8.02 million to $2.43 million.
  • Net operating cash flow has decreased to $12.29 million or 24.10% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm's growth is significantly lower.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Loading ...